Funder: Blood Cancer United (formerly Leukemia & Lymphoma Society)
Due Dates (Anticipated): February 2027 (Full proposals) | September 2027 (Letters of Intent)
Funding Amounts: Recently awarded grant: $2.5 million over five years for clinical trial access research
Summary: Supports research on insurance-related barriers and actionable solutions to improve equitable access to care for blood cancer patients and survivors.
Key Information: Full proposals are by invitation following a Letter of Intent.
Description
Blood Cancer United, formerly the Leukemia & Lymphoma Society, runs the Equity in Access Research Program to help ensure more equitable care for blood cancer patients and survivors. The program seeks evidence that can guide policy reform and changes in healthcare practice, mitigating the effects of social, economic, and environmental disadvantages.
The current research focus, “Understanding How Health Insurance Affects Equity in Access to Care for Individuals Diagnosed with Blood Cancer,” examines how insurance status, type, design, and policy changes create barriers to cancer care. It emphasizes actionable solutions. The program has also supported research on interventions to increase therapeutic cancer clinical trial participation among underrepresented groups, including adolescents, young adults, and older adults with blood cancer.
